Zhuhai Sailong Pharmaceutical Co.,Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021
April 29, 2021 at 09:54 am EDT
Share
Zhuhai Sailong Pharmaceutical Co.,Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 68.294 million compared to CNY 32.323 million a year ago. Operating income was CNY 3.720 million compared to operating loss of CNY 3.213 million a year ago. Net income was CNY 2.063 million compared to net loss of CNY 7.562 million a year ago. Basic earnings per share from continuing operations was CNY 0.0117 compared to basic loss per share from continuing operations of CNY 0.043 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
SAILONG PHARMACEUTICAL GROUP CO.,LTD. 
